CAR-T therapy for multiple myeloma and amyloidosis
Part of Blood & lymphatic, Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma or light-chain amyloidosis that has returned or is not responding to treatment.
- For multiple myeloma: you have tried at least 2 prior treatments, including a proteasome inhibitor, an IMiD, or an anti-CD38 antibody.
- For amyloidosis: you have tried at least 1 prior treatment, including a proteasome inhibitor or anti-CD38 antibody.
- You are able to do daily activities with little help (ECOG score 0-2).
- You do not have serious heart, liver, kidney, or blood problems as defined by the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of CAR T-cell therapy that targets a protein called GPRC5D on cancer cells. It's for people with multiple myeloma or AL amyloidosis that has returned or not responded to other treatments.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with multiple myeloma that has come back or not responded to several prior treatments. It aims to see if this therapy can help control the disease.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests an immune therapy made from T cells to attack multiple markers on multiple myeloma cells (including CD138 and BCMA). It may help people whose myeloma has come back or resisted treatment, when there are no curative options left.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
Hear when a new Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.